Search

Your search keyword '"Liakouli, V"' showing total 244 results
Start Over Author "Liakouli, V"
244 results on '"Liakouli, V"'

1. POS0230 CHARACTERISTICS AND DISEASE COURSE OF SSc-ILD PATIENTS WITH GASTROESOPHAGEAL REFLUX – AN ANALYSIS OF THE EUSTAR COHORT

Author

Roth, E., primary, Bruni, C., additional, Petelytska, L., additional, Carreira, P., additional, De Vries-Bouwstra, J. K., additional, Balbir-Gurman, A., additional, Liakouli, V., additional, Moroncini, G., additional, Bergmann, C., additional, Mouthon, L., additional, Denton, C. P., additional, De Santis, M., additional, Cauli, A., additional, Hasler, P., additional, Bernardino, V., additional, Truchetet, M. E., additional, Vonk, M., additional, Del Galdo, F., additional, Hoffmann-Vold, A. M., additional, Distler, O., additional, and Elhai, M., additional

Published
2024
Full Text
View/download PDF

6. Monocytes from patients with rheumatoid arthritis and type 2 diabetes mellitus display an increased production of interleukin (IL)-1β via the nucleotide-binding domain and leucine-rich repeat containing family pyrin 3(NLRP3)-inflammasome activation: a possible implication for therapeutic decision in these patients

Author

Ruscitti, P., Cipriani, P., Di Benedetto, P., Liakouli, V., Berardicurti, O., Carubbi, F., Ciccia, F., Alvaro, S., Triolo, G., and Giacomelli, R.

Published
2015
Full Text
View/download PDF

7. The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts’ Consensus

Author

Giacomelli, R. Afeltra, A. Bartoloni, E. Berardicurti, O. Bombardieri, M. Bortoluzzi, A. Carubbi, F. Caso, F. Cervera, R. Ciccia, F. Cipriani, P. Coloma-Bazán, E. Conti, F. Costa, L. D'Angelo, S. Distler, O. Feist, E. Foulquier, N. Gabini, M. Gerber, V. Gerli, R. Grembiale, R.D. Guggino, G. Hoxha, A. Iagnocco, A. Jordan, S. Kahaleh, B. Lauper, K. Liakouli, V. Lubrano, E. Margiotta, D. Naty, S. Navarini, L. Perosa, F. Perricone, C. Perricone, R. Prete, M. Pers, J.-O. Pitzalis, C. Priori, R. Rivellese, F. Ruffatti, A. Ruscitti, P. Scarpa, R. Shoenfeld, Y. Triolo, G. Tzioufas, A.

Abstract

Autoimmune diseases (AIDs) share similar serological, clinical, and radiological findings, but, behind these common features, there are different pathogenic mechanisms, immune cells dysfunctions, and targeted organs. In this context, multiple lines of evidence suggest the application of precision medicine principles to AIDs to reduce the treatment failure. Precision medicine refers to the tailoring of therapeutic strategies to the individual characteristics of each patient, thus it could be a new approach for management of AIDS which considers individual variability in genes, environmental exposure, and lifestyle. Precision medicine would also assist physicians in choosing the right treatment, the best timing of administration, consequently trying to maximize drug efficacy, and, possibly, reducing adverse events. In this work, the growing body of evidence is summarized regarding the predictive factors for drug response in patients with AIDs, applying the precision medicine principles to provide high-quality evidence for therapeutic opportunities in improving the management of these patients. © 2020

Published
2021

9. THU0073 THE ANTI-ANGIOGENIC ROLE OF TOFACITINIB DURING EXPERIMENTAL MODEL OF ARTHRITIS.

Author

Cipriani, P., primary, DI Benedetto, P., additional, Ruscitti, P., additional, Berardicurti, O., additional, Liakouli, V., additional, Carubbi, F., additional, Panzera, N., additional, Grazia, N., additional, DI Vito Nolfi, M., additional, DI Francesco, B., additional, Maurizi, A., additional, Rucci, N., additional, Teti, A., additional, Zazzeroni, F., additional, Alesse, E., additional, and Giacomelli, R., additional

Published
2020
Full Text
View/download PDF

13. The -670G> A polymorphism in the FAS gene promoter region influences the susceptibility to systemic sclerosis

Author

Liakouli, V., Manetti, M., Pacini, A., Tolusso, B., Fatini, C., Toscano, A., Cipriani, P., Guiducci, S., Bazzichi, L., Codullo, V., Ruocco, L., Dell'Orso, L., Carubbi, F., Marrelli, A., Abbate, R., Bombardieri, S., Ferraccioli, G., Montecucco, C., Valentini, G., Matucci-Cerinic, M., Ibba-Manneschi, L., and Giacomelli, R.

Subjects
Promoters (Genetics) -- Research, Genetic polymorphisms -- Research, Scleroderma (Disease) -- Genetic aspects, Scleroderma (Disease) -- Research, Scleroderma (Disease) -- Risk factors, Systemic scleroderma -- Genetic aspects, Systemic scleroderma -- Research, Systemic scleroderma -- Risk factors, Health
Published
2009

14. The Vessels Contribute to Fibrosis in Systemic Sclerosis

Author

Paola Di Benedetto, Ruscitti, P., Liakouli, V., Cipriani, P., Giacomelli, R., Di Benedetto, Paola, Ruscitti, Piero, Liakouli, Vasiliki, Cipriani, Paola, and Giacomelli, Roberto

Subjects
Endothelial Cell, Myofibroblast, Epithelial-Mesenchymal Transition, Scleroderma, Systemic, integumentary system, Fibrosi, Systemic, Endothelial Cells, Cell Differentiation, Raynaud Disease, Fibrosis, Scleroderma, Humans, Myofibroblasts, Pericytes, Human, Pericyte
Abstract

Microvascular damage, clinically expressed by Raynaud's phenomenon, is generally the first symptom of the disease and the injured vascular cells, both endothelial and perivascular, may transdifferentiate to myofibroblasts, thus leading to collagen deposition in the tissue and consequent fibrosis. Systemic sclerosis (SSc, scleroderma) is complex disease characterized by autoimmunity, vasculopathy, and fibrosis. It has been shown that microvascular damage may be the first symptom of SSc. Injured endothelial cells and pericytes may transdifferentiate into myofibroblasts, the cells responsible for fibrosis and collagen deposition in the tissue. Based on these factors, the process of myofibroblast generation may link two pivotal events of SSc: microvascular damage and fibrosis. Understanding the development, differentiation, and function of myofibroblasts is therefore crucial to individuate early pathogenetic events and develop new therapeutic target for SSc, a condition in which no disease-modifying agents are available. The aim of this review was to discuss the possible origins of myofibroblasts in SSc, highlighting the process of endothelial mesenchymal transition and pericytes to myofibroblast transition and to show how these events may contribute to pathogenesis of the disease.

Published
2019

15. Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis

Author

Giacomelli, R. Afeltra, A. Alunno, A. Bartoloni-Bocci, E. Berardicurti, O. Bombardieri, M. Bortoluzzi, A. Caporali, R. Caso, F. Cervera, R. Chimenti, M.S. Cipriani, P. Coloma, E. Conti, F. D'Angelo, S. De Vita, S. Di Bartolomeo, S. Distler, O. Doria, A. Feist, E. Fisher, B.A. Gerosa, M. Gilio, M. Guggino, G. Liakouli, V. Margiotta, D.P.E. Meroni, P. Moroncini, G. Perosa, F. Prete, M. Priori, R. Rebuffi, C. Ruscitti, P. Scarpa, R. Shoenfeld, Y. Todoerti, M. Ursini, F. Valesini, G. Vettori, S. Vitali, C. Tzioufas, A.G.

Abstract

Autoimmune rheumatic diseases are characterised by an abnormal immune system response, complement activation, cytokines dysregulation and inflammation. In last years, despite many progresses in managing these patients, it has been shown that clinical remission is reached in less than 50% of patients and a personalised and tailored therapeutic approach is still lacking resulting in a significant gap between guidelines and real-world practice. In this context, the need for biomarkers facilitating early diagnosis and profiling those individuals at the highest risk for a poor outcome has become of crucial interest. A biomarker generally refers to a measured characteristic which may be used as an indicator of some biological state or condition. Three different types of medical biomarkers has been suggested: i. mechanistic markers; ii. clinical disease markers; iii. therapeutic markers. A combination of biomarkers from these different groups could be used for an ideal more accurate diagnosis and treatment. However, although a growing body of evidence is focused on improving biomarkers, a significant amount of this information is not integrated on standard clinical care. The overarching aim of this work was to clarify the meaning of specific biomarkers during autoimmune diseases; their possible role in confirming diagnosis, predicting outcome and suggesting specific treatments. © 2018

Published
2019

18. Myofibroblast Cells Expression of CD248 May Contribute to Exacerbate Microvascular Damage during Systemic Sclerosis

Author

Benedetto, Di, P (Di Benedetto, 1 ), Paola), Ross, (Ross, R, Rebecca)(, 2, Cipriani, 3, (Cipriani, P, Esteves, (Esteves, F, 4 ), Filomena), Liakouli, Vasiliki, (Liakouli, V, 1 ), Vasiliki), Ruscitti, Piero, (Ruscitti, P, 1 ), Piero), Carubbi, (Carubbi, F, 1 ), Francesco), Berardicurti, Onorina, (Berardicurti, O, 1 ), Onorina), Panzera, Noemi, (Panzera, N, 1 ), Noemi), Bartolomeo, Di, S (Di Bartolomeo, 1 ), Salvatore), Galloni, (Galloni, C, 5 ), Chiara), Mavria, (Mavria, G, 5 ), Georgia), Del, Galdo, F (Del Galdo, Francesco)(, 2, Giacomelli, 3, (Giacomelli, R, and Giacomelli, Roberto

Published
2018

19. CARDIAC MAGNETIC RESONANCE IMAGING WITH PHARMACOLOGICAL STRESS PERFUSION IN ASYMPTOMATIC PATIENTS WITH SYSTEMIC SCLEROSIS

Author

Ruscitti, P, Di Cesare, E, Cipriani, P, Di Sibio, A, Liakouli, V, Gennarelli, A, Carubbi, F, Splendiani, A, Berardicurti, O, Di Benedetto, P, Ciccia, F, Guggino, G, Radchenko, G, Triolo, G, Masciocchi, C, Giacomelli, R, Ruscitti, P, Di Cesare, E, Cipriani, P, Di Sibio, A, Liakouli, V, Gennarelli, A, Carubbi, F, Splendiani, A, Berardicurti, O, Di Benedetto, P, Ciccia, F, Guggino, G, Radchenko, G, Triolo, G, Masciocchi, C, and Giacomelli, R

Published
2016

21. International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?: The unmet needs and the clinical grey zone in autoimmune disease management

Author

Giacomelli, R. Afeltra, A. Alunno, A. Baldini, C. Bartoloni-Bocci, E. Berardicurti, O. Carubbi, F. Cauli, A. Cervera, R. Ciccia, F. Cipriani, P. Conti, F. De Vita, S. Di Benedetto, P. Doria, A. Drosos, A.A. Favalli, E.G. Gandolfo, S. Gatto, M. Grembiale, R.D. Liakouli, V. Lories, R. Lubrano, E. Lunardi, C. Margiotta, D.P.E. Massaro, L. Meroni, P. Minniti, A. Navarini, L. Pendolino, M. Perosa, F. Pers, J.-O. Prete, M. Priori, R. Puppo, F. Quartuccio, L. Ruffatti, A. Ruscitti, P. Russo, B. Sarzi-Puttini, P. Shoenfeld, Y. Somarakis, G.A. Spinelli, F.R. Tinazzi, E. Triolo, G. Ursini, F. Valentini, G. Valesini, G. Vettori, S. Vitali, C. Tzioufas, A.G.

Abstract

Autoimmune diseases are a complex set of diseases characterized by immune system activation and, although many progresses have been done in the last 15 years, several unmet needs in the management of these patients may be still identified. Recently, a panel of international Experts, divided in different working groups according to their clinical and scientific expertise, were asked to identify, debate and formulate a list of key unmet needs within the field of rheumatology, serving as a roadmap for research as well as support for clinicians. After a systematic review of the literature, the results and the discussions from each working group were summarised in different statements. Due to the differences among the diseases and their heterogeneity, a large number of statements was produced and voted by the Experts to reach a consensus in a plenary session. At all the steps of this process, including the initial discussions by the steering committee, the identification of the unmet needs, the expansion of the working group and finally the development of statements, a large agreement was attained. This work confirmed that several unmet needs may be identified and despite the development of new therapeutic strategies as well as a better understanding of the effects of existing therapies, many open questions still remain in this field, suggesting a research agenda for the future and specific clinical suggestions which may allow physicians to better manage those clinical conditions still lacking of scientific clarity. © 2017

Published
2017

23. Use of Rituximab in the Management of Sjögren’s Syndrome

Author

Carubbi F, Alunno A, Cipriani P, Berardicurti O, Ruscitti P, Liakouli V, Ciccia F, Triolo F, Gerli R, Giacomelli R., Carubbi, F, Alunno, A, Cipriani, P, Berardicurti, O, Ruscitti, P, Liakouli, V, Ciccia, F, Triolo, F, Gerli, R, and Giacomelli, R.

Published
2015

24. FRI0437 Decreased Expression of Angiopoetin 1 on Perivascular Mesenchymal Stem Cells from SSC Patients Induces an Anti Angiogenetic Effect, when Co-Cultured with Endothelial Cells

Author

Di Benedetto, P. Ruscitti P, Liakouli V, Carubbi F, Berardicurti O, Pantano I, Campese A.F, Alesse E, Screpanti I, Giacomelli R, Cipriani P., Di, Benedetto, P., Ruscitti P, Liakouli, V, Carubbi, F, Berardicurti, O, Pantano, I, Campese, A. F., Alesse, E, Screpanti, I, Giacomelli, R, and Cipriani, P.

Published
2015

25. Macitentan inhibits the transforming growth factor-βprofibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts

Author

9. Cipriani P, Di Benedetto P, Ruscitti P, Verzella D, Fischietti M, Zazzeroni F, Liakouli V, Carubbi F, Berardicurti O, Alesse E, Giacomelli R., 9., Cipriani P, Di Benedetto, P, Ruscitti, P, Verzella, D, Fischietti, M, Zazzeroni, F, Liakouli, V, Carubbi, F, Berardicurti, O, Alesse, E, and Giacomelli, R.

Published
2015

27. Evaluation of the influence of social, demographic, environmental, work-related factors and/or lifestyle habits on Raynaud's phenomenon: a case–control study.

Author

Prete, M., Favoino, E., Giacomelli, R., Afeltra, A., Cantatore, F. P., Bruno, C., Corrado, A., Emmi, L., Emmi, G., Grembiale, R. D., Navarini, L., Marcoccia, A., Liakouli, V., Riccardi, A., Valentini, G., and Perosa, F.

Subjects
RAYNAUD'S disease, SOCIAL influence, CASE-control method, CONTACT lenses, HABIT, CONNECTIVE tissues
Abstract

Raynaud's phenomenon (RP) is a clinical disorder characterized by recurrent, reversible episodes of digital vasospasm. RP can be classified as primary (pRP) or secondary, depending on whether it occurs as a benign condition (not disease-associated) or is associated with other diseases, mainly of the connective tissues. In both cases, it can be triggered by environmental factors, as indicated by the increased incidence of pRP episodes following exposure to cold, vibration injury or chemicals. The purpose of this prospective case–control study was to assess, in an Italian cohort of 132 pRP patients, the association of the phenomenon with demographic, lifestyle habits, environmental and work-related factors. Compared to healthy controls, pRP was found to be inversely associated with the use of contact lenses (OR = 0.4; p = 0.004) and of chlorous-based disinfectants (OR = 0.3; p < 0.001) and directly associated with the presence of prosthesis implants (OR = 5.3; p = 0.001) and the use of hydrogen peroxide-based compounds (OR = 2.6; p = 0.002), suggesting that the latter should be avoided in RP affected patients. Multivariate and multivariable analysis confirmed the associations. Further investigations are needed to understand the mechanism(s) underlying these findings. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

28. FRI0414 Evaluation of a novel multi-analyte assay for the detection of autoantibodies in the diagnosis of systemic sclerosis

Author

Meroni, P.L., primary, Schioppo, T., additional, Ingegnoli, F., additional, Borghi, M.O., additional, Milo, J.L., additional, Bentow, C., additional, Seaman, A., additional, Valentini, G., additional, Vettori, S., additional, Di Benedetto, P., additional, Liakouli, V., additional, Giacomelli, R., additional, and Mahler, M., additional

Published
2018
Full Text
View/download PDF

29. SAT0641 Performance and agreement of different operators and histological techniques for the assessment of germinal centres in minor salivary glands in primary sjÖgren’s syndrome

Author

Alunno, A., primary, Cipriani, P., additional, Coletti, G., additional, Bigerna, B., additional, Manetti, M., additional, Di Benedetto, P., additional, Bistoni, O., additional, Cipolloni, G., additional, Liakouli, V., additional, Ruscitti, P., additional, Gerli, R., additional, Giacomelli, R., additional, and Carubbi, F., additional

Published
2018
Full Text
View/download PDF

40. FRI0613 H-ferritin and pro-inflammatory cytokines are increased in the bone marrow of adult patients affected by macrophage activation syndrome

Author

Ruscitti, P, primary, Cipriani, P, additional, Ciccia, F, additional, Benedetto, P Di, additional, Lizzi, AR, additional, Liakouli, V, additional, Berardicurti, O, additional, Carubbi, F, additional, Guggino, G, additional, D'Andrea, G, additional, Triolo, G, additional, and Giacomelli, R, additional

Published
2017
Full Text
View/download PDF

45. SENESCENT BONE MARROW DERIVED MESENCHYMAL STEM CELLS (MSC) ARE PRONE TO RECOVER DURING SSC

Author

Cipriani, Paola, Di Benedetto, P., Marrelli, A., Liakouli, V., Carubbi, F., Ruscitti, P., Alvaro, S., Del Papa, B., Di Padova, M., Di Ianni, M., Alesse, Edoardo, Giacomelli, Roberto, Paola, Cipriani, Di Benedetto, P., Marrelli, A., Liakouli, V., Carubbi, F., Ruscitti, P., Alvaro, S., Del Papa, B., Di Padova, M., Di Ianni, M., Edoardo, Alesse, and Roberto, Giacomelli

Published
2011

48. Association of FASG670A gene polymorphism with systemic sclerosis

Author

Ibba-Manneschi L, Liakouli V, Pacini A, Manetti M, Tolusso B, Cipriani P, Toscano A, Guiducci S, Cinelli M, Fatini C, Milia A.F, Abbate R, Bombardieri S, Ferraccioli G, Montecucco C, Valentini G, Matucci-Cerinic M, Giacomelli R., Ibba-Manneschi, L, Liakouli, V, Pacini, A, Manetti, M, Tolusso, B, Cipriani, P, Toscano, A, Guiducci, S, Cinelli, M, Fatini, C, Milia, A. F., Abbate, R, Bombardieri, S, Ferraccioli, G, Montecucco, C, Valentini, G, Matucci-Cerinic, M, and Giacomelli, R.

Published
2007

49. Differential expression of stromal cell-derived factor 1 and its receptor CXCR4 in the skin and endothelial cells of systemic sclerosis patients: Pathogenetic implications

Author

CIPRIANI, PAOLA, LIAKOULI V, PACINI A, MANETTI M, MARRELLI A, TOSCANO A, PINGIOTTI E, FULMINIS A, GUIDUCCI S, PERRICONE R, KAHALEH B, MATUCCI CERINIC M, IBBA MANNESCHI L, GIACOMELLI, Roberto, Cipriani, Paola, Liakouli, V, Pacini, A, Manetti, M, Marrelli, A, Toscano, A, Pingiotti, E, Fulminis, A, Guiducci, S, Perricone, R, Kahaleh, B, MATUCCI CERINIC, M, IBBA MANNESCHI, L, and Giacomelli, Roberto

Abstract

Objective. Systemic sclerosis (SSc) is characterized by early endothelial damage evolving to vascular desertification. Stromal cell–derived factor 1 (SDF-1) and its receptor CXCR4 regulate specific steps in new vessel formation. We undertook this study to determine whether an alteration of the SDF-1/CXCR4 axis might be involved in the pathogenetic mechanisms following ischemic damage during SSc. Methods. We enrolled 36 SSc patients and 15 controls. Skin biopsy samples were obtained from each subject, and the expression of SDF-1 and CXCR4 was assessed by immunohistochemistry, reverse transcription– polymerase chain reaction (RT-PCR), and Western blot analyses. Furthermore, isolated microvascular endothelial cells (MVECs) from 4 patients with diffuse cutaneous SSc (dcSSc) and 3 controls were analyzed for SDF-1 and CXCR4 by confocal laser scanning microscopy, RT-PCR, and Western blotting. Results. SDF-1 and CXCR4 were up-regulated in the skin of patients with early (edematous) SSc, both in the diffuse and limited cutaneous forms, and progressively decreased, with the lowest expression in the latest phases of both SSc subsets. MVECs from patients with dcSSc expressed significantly higher amounts of both isoforms of SDF-1 in the early stage of disease, with a progressive reduction of SDF-1 and CXCR4 in later stages. On the surface of cultured MVECs from patients with dcSSc, SDF-1 and CXCR4 colocalized in polarized areas, suggesting that they are activated in vivo and that they are under strict genetic control to retain capping function. Conclusion. Due to its transient expression, SDF-1 could be considered a future therapeutic target to induce new vessel formation in SSc.

Published
2006

50. Differential expression of SDF-1 and its receptor CXCR4 in the skin and endothelial cells of systemic sclerosis patients: Pathogenetic implication

Author

Cipriani P, Liakouli V, Milia A.F, Pacini A, Manetti M, Marrelli A, Toscano A, Pingiotti E, Fulminis A, Guiducci S, Perricone R, Kahaleh B, Matucci-Cerinic M, Ibba-Manneschi L, Giacomelli R., Cipriani, P, Liakouli, V, Milia A., F, Pacini, A, Manetti, M, Marrelli, A, Toscano, A, Pingiotti, E, Fulminis, A, Guiducci, S, Perricone, R, Kahaleh, B, Matucci-Cerinic, M, Ibba-Manneschi, L, and Giacomelli, R.

Subjects
Settore MED/12 - Gastroenterologia
Published
2006

Catalog

Books, media, physical & digital resources
See catalog results